<DOC>
	<DOCNO>NCT01999270</DOCNO>
	<brief_summary>To determine FDOPA-PET/MRI image predict response treatment bevacizumab .</brief_summary>
	<brief_title>Evaluation FDOPA-PET/MRI Pediatric Patients With CNS Tumors</brief_title>
	<detailed_description>Evaluate feasibility use FDOPA-PET/MRI pediatric patient CNS tumor . Positive result small study would provide data need expand study validate use large population pediatric patient . Validating use FDOPA-PET image early predictor response anti-angiogenic therapy could greatly impact standard care treat evaluate pediatric brain tumor provide useful biomarker assess experimental therapeutic .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Ganglioglioma</mesh_term>
	<mesh_term>Ganglioneuroma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patient must histological verification one eligible diagnosis list . Biopsy require time diagnosis , exception optic pathway tumor . Patients spinal cord disease eligible lesion &gt; 1 cm 2 dimension . The following histology eligible : Astrocytoma variant : fibrillary , protoplasmic , mixed Pilocytic astrocytoma , include pilomyxoid variant Pleomorphic xanthoastrocytoma Infantile desmoplastic astrocytoma Ganglioneuroma Oligodendroglial tumor Mixed glioma ( include oligoastrocytoma ) Anaplastic astrocytoma Anaplastic oligoastrocytoma Anaplastic oligodendroglioma Anaplastic ganglioglioma Glioblastoma multiforme ( include giant cell gliosarcoma type ) Medulloblastoma Ependymoma Other rare malignant CNS tumor ( i.e. , pineal blastoma , small cell astrocytoma , etc . ) Patient must ≤ 21 year age time study enrollment . Patient must measurable residual disease , define tumor measurable two perpendicular diameter MRI . Diffuse leptomeningeal disease consider measurable . Patient must Lansky Karnofsky performance &gt; 40 % correspond ECOG category 0 , 1 , 2 . Karnofsky use patient &gt; 16 year age Lansky patient &lt; 16 year age . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Patient must life expectancy &gt; 8 week . Patient must fully recover acute toxic effect prior chemotherapy radiation prior enter study . Patient must recover surgical procedure enrol study . Hypertensive patient eligible provided hypertension well control ( 95th percentile age height patient ≤17 year ) stable dos medication . ( See Appendices I II table blood pressure base age gender ) . Patients receive corticosteroid eligible provide dose stable decrease least 7 day . Patient must adequate bone marrow function ( include status postSCT ) define : 1 . Peripheral absolute neutrophil count ( ANC ) ≥1000/uL ( must receive GCSF within prior 7 day ) 2 . Platelet count ≥ 100,000/uL ( transfusion independent ) 3 . Hemoglobin ≥ 8.0 gm/dL ( may receive pRBC transfusion ) Patient must adequate renal function define : 1 . Creatinine clearance radioisotope GFR ≥70ml/min/1.73 m2 2 . A serum creatinine base age/gender follow : 1 month &lt; 6 month , male max 0.4 , female max 0.4 6 month &lt; 1 year , male max 0.5 , female max 0.5 1 &lt; 2 year , male max 0.6 , female max 0.6 2 &lt; 6 year , male max 0.8 , female max 0.8 6 &lt; 10 year , male max 1.0 , female max 1.0 10 &lt; 13 year , male max 1.2 , female max 1.2 13 &lt; 16 year , male max 1.5 , female max 1.4 16 year , male max 1.7 , female max 1.4 Urine protein screen dipstick analysis . If protein ≥ 2+ dipstick , Urine Protein Creatinine ( UPC ) ratio calculate . If UPC ratio &gt; 1 , 24hour urine protein obtain level &lt; 1000 mg/24 hour patient enrollment . Note : UPC ratio spot urine estimation 24 hour urine protein excretion UPC ratio 1 roughly equivalent 24hour urine protein 1 gm . UPC ratio calculate use follow formula : [ urine protein ] / [ urine creatinine ] protein creatinine report mg/dL [ ( urine protein x 0.088 ] / [ urine creatinine ] urine creatinine report mmol/L Patient must adequate liver function define : 1 . Total bilirubin ≤1.5x upper limit normal age ( ULN ) 2 . SGPT ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) age Patients seizure disorder eligible wellcontrolled anticonvulsant . If nonenzyme inducing anticonvulsant , irinotecan dose adjust outline treatment plan . Sexually active patient childbearing potential must agree use effective method contraception study least 6 month completion bevacizumab therapy . Patient legally authorize representative must able understand willing sign write informed consent document . Patient must myelosuppressive chemotherapy ≤ 3 week prior entry onto study ( 6 week prior nitrosourea ) . Patient must antineoplastic biologic agent ≤7 day prior entry onto study ( least 3 halflives biologic agent long halflife ) . Patient must receive craniospinal radiotherapy involve field radiotherapy local tumor ( and/or tumor designate `` measurable '' protocol purpose ) ≤ 24 week prior study entry ; focal radiation area symptomatic metastatic disease must give within 14 day study entry . Patient must receive bevacizumab , antiVEGF inhibitor last 3 month . Patient must require major surgical procedure ≤ 21 day prior begin therapy . Patient must require intermediate surgical procedure ≤14 day prior begin therapy . Patient must require minor surgical procedure ( i.e. , Broviac line infusaport placement ) ≤ 7 day prior begin therapy , wound must heal prior initiation therapy . There anticipation need major surgical procedure course study . Patient must receive growth factor ≤7 day entry onto study . Patient must take NSAIDS , clopidogrel , dipyridamole , aspirin therapy &gt; 81 mg/day . Patient must serious nonhealing wound , ulcer , bone fracture . Patient must require sedation imaging purpose . Patient must receive investigational drug . Patient must receive anticancer agent . Patient must uncontrolled infection . Patient must history abdominal fistula , gastrointestinal perforation intraabdominal abscess ≤ 6 month prior study entry . Patient must know bleed diathesis coagulopathy . Patient must significant vascular disease ( e.g. , MoyaMoya , aortic aneurysm require surgical repair , deep venous arterial thrombosis ) ≤ 6 month prior study entry . Patient must know thrombophilic condition ( i.e . protein S , protein C antithrombin III deficiency , Factor V Leiden , Factor II G20210A mutation , homocysteinemia , antiphospholipid antibody syndrome ) . Testing required patient without thrombophilic history . Patient must evidence new CNS hemorrhage great 0.5cm baseline MRI obtain ≤ 14 day prior study enrollment . Patient must history stroke , myocardial infarction , transient ischemic attack ( TIA ) , severe unstable angina , peripheral vascular disease , grade II great congestive heart failure ≤ 6 month prior study entry . Patient must serious inadequately control cardiac arrhythmia Patient must pregnant breastfeeding . Patient must know hypersensitivity Chinese hamster ovary cell product recombinant human antibody . Patient must know HIVpositive combination antiretroviral therapy potential pharmacokinetic interaction study therapy . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Patient must contraindications MRI image include implanted medical device metal object may adversely affect MRI image . All subject require complete standard MRI screening form prior imaging .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>